drugset / Trial / NCT03153319
Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI
Phase 1/2
Active not recruiting
14 enrolled
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
McGill University Health Centre/Research Institute of the McGill University Health Centre · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Randomized, double-blind, placebo-controlled, parallel-group, single-center study followed by open-label phase, to evaluate the effects of adalimumab compared to placebo on the change from baseline in joint and skeletal disease in children and adults with mucopolysaccharidosis (MPS) I, II or VI.
Timeline
- Start
- 2017-06-05
- Primary completion
- 2027-01
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 20 mg | Subcutaneous |
| Subject | Adalimumab | Monoclonal antibody | 40 mg | Subcutaneous |